 Kazia Therapeutics Limited ASX: KZA; NASDAQ: KZIA, an Australian oncology-focused biotechnology company, is pleased to announce that its lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase II III study in glioblastoma. It is expected that data from GBM AGILE will be used to seek marketing approval for GDC-0084 from FDA and other regulatory agencies. 